Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Woot de Trixhe

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2021
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapyXavier Woot de Trixhe, Wojciech Krzyzanski, An Vermeulen, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|July 12, 2018
A robust simulator for physiologically structured population modelsMichiel Van Dyck, Xavier Woot de Trixhe, An Vermeulen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 5, 2015
The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response modelsAdrian Dunne, Willem de Winter, Chyi-Hung Hsu, et al.
British Journal of Clinical Pharmacology|February 1, 2017
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozinWillem de Winter, Adrian Dunne, Xavier Woot de Trixhe, et al.
Therapeutic Advances in Hematology|December 30, 2025
Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration routeJonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, et al.
Computational and Structural Biotechnology Journal|September 30, 2021
A quantitative systems pharmacology model for acute viral hepatitis BEduardo Asín-Prieto, Zinnia P Parra-Guillen, José David Gómez Mantilla, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 14, 2019
Immune network for viral hepatitis B: Topological representationEduardo Asín-Prieto, Zinnia P Parra-Guillen, José David Gómez Mantilla, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesEleonora Marostica, Juthamas Sukbuntherng, David Loury, et al.
Journal of the Royal Society, Interface|June 10, 2026
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infectionClare McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
AIDS (London, England)|April 8, 2021
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of ageChristine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2021
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapyXavier Woot de Trixhe, Wojciech Krzyzanski, An Vermeulen, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics|July 12, 2018
A robust simulator for physiologically structured population modelsMichiel Van Dyck, Xavier Woot de Trixhe, An Vermeulen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 5, 2015
The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response modelsAdrian Dunne, Willem de Winter, Chyi-Hung Hsu, et al.
British Journal of Clinical Pharmacology|February 1, 2017
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozinWillem de Winter, Adrian Dunne, Xavier Woot de Trixhe, et al.
Therapeutic Advances in Hematology|December 30, 2025
Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration routeJonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, et al.
Computational and Structural Biotechnology Journal|September 30, 2021
A quantitative systems pharmacology model for acute viral hepatitis BEduardo Asín-Prieto, Zinnia P Parra-Guillen, José David Gómez Mantilla, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 14, 2019
Immune network for viral hepatitis B: Topological representationEduardo Asín-Prieto, Zinnia P Parra-Guillen, José David Gómez Mantilla, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesEleonora Marostica, Juthamas Sukbuntherng, David Loury, et al.
Journal of the Royal Society, Interface|June 10, 2026
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infectionClare McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
AIDS (London, England)|April 8, 2021
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of ageChristine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, et al.
Pageof 1